| Autor: |
Cass SP; King's Centre for Lung Health, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, Guy's Hospital, King's College London, London SE1 9RT, UK; King's College London, London SE1 9RT, UK. Electronic address: steven.cass@kcl.ac.uk., Cope AP; Centre for Rheumatic Diseases, Department of Inflammation Biology, King's College London, London SE1 9RT, UK., Nicolau DV Jr; King's Centre for Lung Health, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, Guy's Hospital, King's College London, London SE1 9RT, UK; King's College London, London SE1 9RT, UK., Russell REK; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Bafadhel M; King's Centre for Lung Health, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, Guy's Hospital, King's College London, London SE1 9RT, UK; King's College London, London SE1 9RT, UK. |
| Abstrakt: |
Competing Interests: SPC, APC, and DVN Jr declare no competing interests. REKR discloses consultancy or speaker fees paid to their institution from AstraZeneca, Chiesi, and GlaxoSmithKline, is a scientific advisor to GlaxoSmithKline, and discloses support for attending meetings from Boehringer Ingelheim. MB discloses grants paid to their institution from AstraZeneca, Roche, and Asthma & Lung UK, has received consultancy or speaker fees paid to their institution from AstraZeneca, Chiesi, GlaxoSmithKline, and Sanofi, and is a scientific advisor to ProAxsis and AlbusHealth. |
